Draft:Antibody Therapeutics

From Wikipedia, the free encyclopedia

Antibody Therapeutics is a quarterly peer-reviewed open-access scientific journal focused on the development and application of antibody-based therapies. It was established in 2018 and is published by Oxford University Press on behalf of ChAbS (Chinese Antibody Society). The editor-in-chief is Mitchell Ho (National Institutes of Health).[1]

  • Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. Danwang504 (talk) 20:29, 22 March 2026 (UTC)

DisciplineImmunology, Oncology, Antibody engineering
LanguageEnglish
EditedbyMitchell Ho
History2018–present
Quick facts Discipline, Language ...
Antibody Therapeutics
DisciplineImmunology, Oncology, Antibody engineering
LanguageEnglish
Edited byMitchell Ho
Publication details
History2018–present
Publisher
Oxford University Press (United Kingdom)
FrequencyQuarterly
Yes
4.5 (2024)
Standard abbreviations
ISO 4Antib. Ther.
Indexing
ISSN2516-4236
Links
Close

History

The journal was launched in 2018 through a partnership between Oxford University Press and ChAbS.[2] It was established as an open-access publication to provide a platform for the latest advances in therapeutic antibody research.[1]

Scope

The journal covers all aspects of therapeutic antibody research, including target and antibody discovery, therapeutic antibody engineering and development, mechanistic research, new technologies and methods, manufacturing, clinical trials, and regulatory policies. It publishes original research articles, reviews and methodological papers.[1]

Abstracting and indexing

The journal is abstracted and indexed in the following databases:[1]

According to Journal Citation Reports, the journal has a 2024 impact factor of 4.5.[7]

References

Related Articles

Wikiwand AI